{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T17:43:33Z","timestamp":1782927813707,"version":"3.54.5"},"reference-count":29,"publisher":"Spandidos Publications","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Int"],"DOI":"10.3892\/mi.2024.210","type":"journal-article","created":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T12:02:37Z","timestamp":1733227357000},"source":"Crossref","is-referenced-by-count":3,"title":["Myositis\/myasthenia gravis caused by immune checkpoint inhibition: A report of two cases and a brief review of the literature"],"prefix":"10.3892","volume":"5","author":[{"given":"Zenia","family":"Elavia","sequence":"first","affiliation":[{"name":"Department of Neurology, University of Alabama, Birmingham, AL 35294, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Jimenez","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Alabama, Birmingham, AL 35294, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxanne","family":"Lockhart","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Alabama, Birmingham, AL 35294, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Muha","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Alabama, Birmingham, AL 35294, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Kazamel","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Alabama, Birmingham, AL 35294, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2024,12,3]]},"reference":[{"key":"key20250103130749_b1-MI-5-1-00210","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: A systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"key20250103130749_b2-MI-5-1-00210","doi-asserted-by":"publisher","first-page":"424","DOI":"10.14740\/jmc3783","article-title":"Nivolumab, a Double-Edged Sword: A case report of nivolumab-induced myasthenia gravis","volume":"12","author":"Tahir","year":"2021","journal-title":"J Med Cases"},{"key":"key20250103130749_b3-MI-5-1-00210","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1093\/annonc\/mdr028","article-title":"Anti-CTLA-4 antibody-induced Guillain-Barre syndrome in a melanoma patient","volume":"22","author":"Wilgenhof","year":"2011","journal-title":"Ann Oncol"},{"key":"key20250103130749_b4-MI-5-1-00210","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1001\/jamaneurol.2017.1912","article-title":"Neurological complications associated with anti-programmed death 1 (PD-1) antibodies","volume":"74","author":"Kao","year":"2017","journal-title":"JAMA Neurol"},{"key":"key20250103130749_b5-MI-5-1-00210","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1097\/WCO.0000000000000391","article-title":"Neurologic complications of immune checkpoint inhibitors","volume":"29","author":"Hottinger","year":"2016","journal-title":"Curr Opin Neurol"},{"key":"key20250103130749_b6-MI-5-1-00210","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1080\/14740338.2020.1738382","article-title":"Neurologic complications of immune checkpoint inhibitors","volume":"19","author":"Haugh","year":"2020","journal-title":"Expert Opin Drug Saf"},{"issue":"319","key":"key20250103130749_b7-MI-5-1-00210","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0774-y","article-title":"Immune checkpoint inhibitor related myasthenia gravis: Single center experience and systematic review of the literature","volume":"7","author":"Safa","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"518","key":"key20250103130749_b8-MI-5-1-00210","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-023-07987-x","article-title":"Improved outcomes with early immunosuppression in patients with immune-checkpoint inhibitor induced myasthenia gravis, myocarditis and myositis: A case series","volume":"31","author":"Weaver","year":"2023","journal-title":"Support Care Cancer"},{"key":"key20250103130749_b9-MI-5-1-00210","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/mus.20950","article-title":"Lifetime course of myasthenia gravis","volume":"37","author":"Grob","year":"2008","journal-title":"Muscle Nerve"},{"key":"key20250103130749_b10-MI-5-1-00210","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1002\/mus.26689","article-title":"Factors associated with acute exacerbations of myasthenia gravis","volume":"60","author":"Gummi","year":"2019","journal-title":"Muscle Nerve"},{"key":"key20250103130749_b11-MI-5-1-00210","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1001\/archneurol.2009.229","article-title":"Autoimmune targets of heart and skeletal muscles in myasthenia gravis","volume":"66","author":"Suzuki","year":"2009","journal-title":"Arch Neurol"},{"key":"key20250103130749_b12-MI-5-1-00210","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.amjoto.2018.06.003","article-title":"Immune checkpoint-mediated myositis and myasthenia gravis: A case report and review of evaluation and management","volume":"39","author":"Kang","year":"2018","journal-title":"Am J Otolaryngol"},{"issue":"63","key":"key20250103130749_b13-MI-5-1-00210","doi-asserted-by":"publisher","DOI":"10.1007\/s11910-018-0878-7","article-title":"Neuromuscular complications of programmed cell death-1 (PD-1) Inhibitors","volume":"18","author":"Kao","year":"2018","journal-title":"Curr Neurol Neurosci Rep"},{"key":"key20250103130749_b14-MI-5-1-00210","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1111\/cas.12961","article-title":"Myasthenic crisis and polymyositis induced by one dose of nivolumab","volume":"107","author":"Kimura","year":"2016","journal-title":"Cancer Sci"},{"issue":"e7350","key":"key20250103130749_b15-MI-5-1-00210","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000007350","article-title":"Nivolumab-induced myasthenia gravis in a patient with squamous cell lung carcinoma: Case report","volume":"96","author":"Chen","year":"2017","journal-title":"Medicine (Baltimore)"},{"issue":"2539493","key":"key20250103130749_b16-MI-5-1-00210","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/2539493","article-title":"Severe myositis, myocarditis, and myasthenia gravis with elevated anti-striated muscle antibody following single dose of ipilimumab-nivolumab therapy in a patient with metastatic melanoma","volume":"2019","author":"Fazel","year":"2019","journal-title":"Case Reports Immunol"},{"key":"key20250103130749_b17-MI-5-1-00210","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1093\/neuonc\/nou001","article-title":"Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma","volume":"16","author":"Liao","year":"2014","journal-title":"Neuro Oncol"},{"key":"key20250103130749_b18-MI-5-1-00210","doi-asserted-by":"publisher","first-page":"e122","DOI":"10.1200\/JCO.2013.51.1683","article-title":"Myasthenia gravis induced by ipilimumab in patients with metastatic melanoma","volume":"33","author":"Johnson","year":"2015","journal-title":"J Clin Oncol"},{"key":"key20250103130749_b19-MI-5-1-00210","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1002\/mus.24648","article-title":"Myasthenia gravis associated with ipilimumab and nivolumab in the treatment of small cell lung cancer","volume":"52","author":"Loochtan","year":"2015","journal-title":"Muscle Nerve"},{"key":"key20250103130749_b20-MI-5-1-00210","first-page":"119","article-title":"Nivolumab for the treatment of malignant melanoma in a patient with pre-existing myasthenia gravis","volume":"78","author":"Maeda","year":"2016","journal-title":"Nagoya J Med Sci"},{"key":"key20250103130749_b21-MI-5-1-00210","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1002\/mus.25212","article-title":"Benign form of myasthenia gravis after nivolumab treatment","volume":"54","author":"Sciacca","year":"2016","journal-title":"Muscle Nerve"},{"key":"key20250103130749_b22-MI-5-1-00210","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1093\/jjco\/hyv158","article-title":"Acetylcholine receptor binding antibody-associated myasthenia gravis and rhabdomyolysis induced by nivolumab in a patient with melanoma","volume":"46","author":"Shirai","year":"2016","journal-title":"Jpn J Clin Oncol"},{"issue":"507","key":"key20250103130749_b23-MI-5-1-00210","doi-asserted-by":"publisher","DOI":"10.1002\/mus.25163","article-title":"Myasthenia gravis induced by nivolumab therapy in a patient with non-small-cell lung cancer","volume":"54","author":"Polat","year":"2016","journal-title":"Muscle Nerve"},{"key":"key20250103130749_b24-MI-5-1-00210","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1097\/CJI.0000000000000161","article-title":"Myasthenia gravis after nivolumab therapy for squamous cell carcinoma of the bladder","volume":"40","author":"Chang","year":"2017","journal-title":"J Immunother"},{"issue":"e9262","key":"key20250103130749_b25-MI-5-1-00210","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000009262","article-title":"Coexisting myasthenia gravis, myositis, and polyneuropathy induced by ipilimumab and nivolumab in a patient with non-small-cell lung cancer: A case report and literature review","volume":"96","author":"Chen","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"key20250103130749_b26-MI-5-1-00210","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1097\/CAD.0000000000000903","article-title":"Myositis and myasthenia during nivolumab administration for advanced lung cancer: A case report and review of the literature","volume":"31","author":"Veccia","year":"2020","journal-title":"Anticancer Drugs"},{"issue":"5126717","key":"key20250103130749_b27-MI-5-1-00210","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/5126717","article-title":"The terrible triad of checkpoint inhibition: A case report of myasthenia gravis, myocarditis, and myositis induced by cemiplimab in a patient with metastatic cutaneous squamous cell carcinoma","volume":"2020","author":"Jeyakumar","year":"2020","journal-title":"Case Reports Immunol"},{"key":"key20250103130749_b28-MI-5-1-00210","doi-asserted-by":"publisher","first-page":"NP123","DOI":"10.1177\/03008916211040559","article-title":"Cemiplimab- and nivolumab-induced myasthenia gravis: Two clinical cases","volume":"107","author":"Canino","year":"2021","journal-title":"Tumori"},{"issue":"e18040","key":"key20250103130749_b29-MI-5-1-00210","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.18040","article-title":"Nivolumab-Induced myasthenia gravis concomitant with myocarditis, myositis, and hepatitis","volume":"13","author":"Bawek","year":"2021","journal-title":"Cureus"}],"container-title":["Medicine International"],"original-title":[],"deposited":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T11:07:52Z","timestamp":1735902472000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/mi.2024.210"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,3]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12,3]]}},"URL":"https:\/\/doi.org\/10.3892\/mi.2024.210","relation":{},"ISSN":["2754-3242","2754-1304"],"issn-type":[{"value":"2754-3242","type":"print"},{"value":"2754-1304","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,3]]},"article-number":"11"}}